• Trials to Test Potential for Immunotherapy Technology

News & Views

Trials to Test Potential for Immunotherapy Technology

Oct 07 2019

Sydney-based Immutep Ltd, developers of immunotherapy treatments for cancer and autoimmune diseases, is to receive a milestone payment from GSK of GB £4 million (approx AU $7.39 million) related to the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis. 

GSK2831781 is derived from Immutep’s IMP731 antibody, a depleting anti-LAG antibody technology that was exclusively licensed to GSK. Under the terms of the agreement, the Australian biotech is eligible to receive up to GB £64 million (approx AU $118.17 million) in developmental milestone payments as well as single-digit tiered royalties, if commercialisation stages are reached. GSK is responsible for all costs associated with the clinical development and the commercialisation process.

Immutep CEO Marc Voigt, said: “It is very encouraging to see GSK advancing their product candidate in a phase II clinical trial for ulcerative colitis, further validating LAG-3 as a potential target for therapeutics in autoimmune diseases. These partner milestone payments are an important source of non-dilutive funding to the company and this capital will be deployed to further advance our extensive development programs.”


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

MEDICA 2024

Nov 11 2024 Dusseldorf, Germany

FILTECH

Nov 12 2024 Cologne, Germany

Intech

Nov 12 2024 Tel Aviv, Israel

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

View all events